104 related articles for article (PubMed ID: 37852870)
1. Carbohydrate fatty acid monosulphate ester is a potent adjuvant for low-dose seasonal influenza vaccines.
Platenburg PPLI; Deschamps F; Jung J; Leonard C; Rusconi S; Mohan Kumar SB; Sulaiman SM; de Waal L; Hilgers LAT
Vaccine; 2023 Nov; 41(47):6980-6990. PubMed ID: 37852870
[TBL] [Abstract][Full Text] [Related]
2. Carbohydrate fatty acid monosulphate esters are safe and effective adjuvants for humoral responses.
Hilgers LAT; Platenburg PPLI; Bajramovic J; Veth J; Sauerwein R; Roeffen W; Pohl M; van Amerongen G; Stittelaar KJ; van den Bosch JF
Vaccine; 2017 May; 35(24):3249-3255. PubMed ID: 28479181
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
[TBL] [Abstract][Full Text] [Related]
4. MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly.
Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
Vaccine; 2022 Mar; 40(10):1472-1482. PubMed ID: 35125224
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
Heldens JG; Glansbeek HL; Hilgers LA; Haenen B; Stittelaar KJ; Osterhaus AD; van den Bosch JF
Vaccine; 2010 Nov; 28(51):8125-31. PubMed ID: 20950729
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant.
Aminzadeh A; Hilgers L; Paul Platenburg P; Riou M; Perrot N; Rossignol C; Cauty A; Barc C; Jørgensen R
Vaccine; 2024 Mar; 42(7):1582-1592. PubMed ID: 38336558
[TBL] [Abstract][Full Text] [Related]
7. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-β-cyclodextrin: A phase 1 clinical trial.
Watanabe A; Nishida S; Burcu T; Shibahara T; Kusakabe T; Kuroda E; Ishii KJ; Kumanogoh A
Vaccine; 2022 Jul; 40(31):4150-4159. PubMed ID: 35672178
[TBL] [Abstract][Full Text] [Related]
9. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets.
Han HJ; Song MS; Park SJ; Byun HY; Robles NJC; Ha SH; Choi YK
J Microbiol; 2019 Feb; 57(2):163-169. PubMed ID: 30706345
[TBL] [Abstract][Full Text] [Related]
11. Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets.
Onishi M; Kitano M; Taniguchi K; Homma T; Kobayashi M; Sato A; Coban C; Ishii KJ
Vaccine; 2014 May; 32(25):3004-9. PubMed ID: 24721532
[TBL] [Abstract][Full Text] [Related]
12. Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant.
Gordon DL; Sajkov D; Honda-Okubo Y; Wilks SH; Aban M; Barr IG; Petrovsky N
Vaccine; 2016 Jul; 34(33):3780-6. PubMed ID: 27342914
[TBL] [Abstract][Full Text] [Related]
13. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.
Layton RC; Petrovsky N; Gigliotti AP; Pollock Z; Knight J; Donart N; Pyles J; Harrod KS; Gao P; Koster F
Vaccine; 2011 Aug; 29(37):6242-51. PubMed ID: 21736913
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
16. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
[TBL] [Abstract][Full Text] [Related]
17. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
18. A nanoemulsion-adjuvanted intranasal H5N1 influenza vaccine protects ferrets against homologous and heterologous H5N1 lethal challenge.
Smith D; Streatfield SJ; Acosta H; Ganesan S; Fattom A
Vaccine; 2019 Sep; 37(42):6162-6170. PubMed ID: 31495593
[TBL] [Abstract][Full Text] [Related]
19. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
20. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.
Forrest HL; Khalenkov AM; Govorkova EA; Kim JK; Del Giudice G; Webster RG
Vaccine; 2009 Jun; 27(31):4187-95. PubMed ID: 19406182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
